COX-1
2.1 μM (IC 50 )
COX-2
1.6 μM (IC 50 )
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent. (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis. (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 µM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1. (S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation. (S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC 50 of 61.7 μM.
Cell Proliferation Assay
Cell Cycle Analysis
Apoptosis Analysis
Western Blot Analysis
(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model.